MB02 Licensing Opportunity MB02 anti CD93 asset in lung squamous cell carcinoma positions Montis as a potential partner for oncology licenses; the asset shows best in class potential in an underserved inflammation driven oncology niche; Montis signals intent to partner this asset, inviting business development discussions with pharma and biotech players seeking novel perivascular targets.

Novel C1q Platform MB01 targets C1q functions beyond the classical complement blockade, offering a first in class mechanism for neuroinflammatory and autoimmune neuropathies; this widens collaboration opportunities for companies pursuing innovative complement modulating therapies across neurology and immunology.

Clinical Milestone Readiness Montis is advancing multiple preclinical and early clinical programs with near term milestones, including MB0109 data and planned Phase 1 activities in 2026; this creates timely collaboration windows for joint development, milestone based deals, or research stage partnerships.

Investor Backing Advantage Backing from premier investors such as Pfizer Ventures and VIB provides credibility and potential co investment signals, easing due diligence and enabling more favorable deal terms for strategic partnerships.

European Collaboration Potential European base and VLAIO fund history, plus access to EU networks, make Montis an attractive partner for Europe focused collaborations, CRO joint development arrangements, and regional manufacturing or clinical development partnerships.